NKCL Bio Group
Inc. (Chairman Dong-Hwa Shin, hereinafter referred to as NKCL) announced that
it had acquired a ‘T-4’ grade, an excellent company certification at Technology
by NICE evaluation information, a nationally accredited technology credit
The Tech Credit
Bureau comprehensively analyzes and evaluates a company's technological progess
by 4 items, such as technology, marketability, business feasibility, and
management capability, and is divided into 10 grades from T-1 to T-10. The
‘T-4’ grade obtained by NKCL this time is the highest grade that a privately
held SME(small and medium-sized enterprises) can receive, which is equivalent
to a grade given to companies with excellent technology for the KOSDAQ
technology special listing.
It is a very rare
case that a company like NKCL, who has been in business for 2 years, has been
selected, this technology evaluation has recognized the excellent technology of
NKCL Bio Group in the field of cell culture.
NKCL Bio Group,
a leading biotech company, researches and develops NK immunotherapy using 'NK
cells', which are responsible for the most important immune system in our body.
The core of the
development of NK cell therapy, which is called the next-generation anticancer
therapy due to its targeted treatment ability against cancer cells, is the mass
proliferation technology of NK cells. By improving the existing NK cell
activity, NKCL Bio Group Inc. has significantly increased the anticancer
the industry, the domestic pharmaceutical bio market is investing intensively
in the development of new drugs and CDMO (consignment development and
production) to secure competitiveness in the next-generation cell therapy and
gene therapy field. Including Samsung Biologics, GC Cell, NK Max, and Box Cell
Bio are continuing their active investment to secure competitiveness in the
NKCL is also building a full-fledged system so that CDMO (Contract Development
a nd Manufacturing Company) in the field of NK cell therapy focusing on the
immunity, the keyword of the business, can proceed smoothly.
plans to accelerate the R&D and production process of NK cell therapy
products by acquiring 3 new patents: a polymer nanoparticle-based anticancer
vaccine composition, a dendritic cell cancer treatment, and a composition for
preventing and treating cancer.
NKCL Bio Group’s
Chairman Dong-hwa Shin said, “The share of next-generation biopharmaceuticals,
NK cell therapy, is gradually increasing in the global pharmaceutical and bio
market. As clinical trials usually account for more than half of the process
for developing new drugs, NKCL is also conducting anticancer efficacy clinical
trials on safety regarding RK-NKTM.”
clinical trial is completed, we expect to receive a higher score in the
valuation as a technology company,” he added.